您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Umibecestat
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Umibecestat
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Umibecestat图片
CAS NO:1387560-01-1
包装与价格:
包装价格(元)
5mg电议
10mg电议

产品介绍
Umibecestat (CNP520) 是一种 β 位点淀粉样前体蛋白裂解酶-1 (BACE-1) 抑制剂, 在人 BACE-1 和鼠 BACE-1 中的 IC50 值分别为 11 nM 和 10 nM。Umibecestat 可用于阿尔茨海默病的研究。
Cas No.1387560-01-1
别名CNP520
分子式C19H15ClF7N5O2
分子量513.8
溶解度DMSO : 100 mg/mL (194.63 mM; Need ultrasonic)
储存条件4°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Umibecestat (CNP520) is a beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) inhibitor with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively[1]. Umibecestat can be used for the research of alzheimer's disease.

Umibecestat (CNP520) is a potent BACE-1 inhibitor that is selective for BACE-1 over other human pepsin-like aspartic proteases, including BACE-2 and cathepsin D[1].

Umibecestat (CNP520) (1.5-51.3 mg/kg; given by oral gavage; 72 hours) shows a dose-dependent effects on Aβ40 and a long duration of action in both rat brain and CSF[1].Umibecestat (CNP520) (3.1 mg/kg; oral administration; 7 days) shows a >75% reduction on Aβ40 and Aβ42 in CSF after dosing and returns slowly to baseline over the next 7 days[1].

[1]. Neumann U, et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. EMBO Mol Med. 2018 Nov;10(11). pii: e9316.